Tysabri® Demonstrates Significant Health-Related Quality Of Life Improvements For Multiple Sclerosis Patients Medical News Today Sun, 26 Aug 2007 8:11 PM PDT Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today the publication of results demonstrating that patients treated with TYSABRI® (natalizumab) showed a significant improvement in health-related quality of life (HRQoL) measures when compared to placebo. [click link for full article]